Artiva developed AlloNK, an investigational donor-derived natural killer cell therapy for autoimmune diseases. It has discontinued development of its lead candidate and is evaluating strategic alternatives, including a potential transaction or liquidation.
Artiva's AlloNK-led investment case has ended: development is discontinued, the planned Phase 3 will not start, and longer-term response durability fell short of management's requirements. A fatal neurological event was assessed as likely fludarabine-related. The company is cutting its workforce by approximately 94% and pursuing strategic alternatives, including a possible transaction or liquidation. Approximately $319.1 million in preliminary, unaudited cash, cash equivalents and investments at September 30, 2026 provides a financial base, but shareholder recovery depends on costs and the eventual outcome.
Thesis checklist
3 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: The November update supports the Phase 2a signal
Would detailed RA follow-up support the earlier response signal despite the company's durability concerns?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Artiva ends AlloNK development and pursues strategic alternatives
AlloNK's Phase 3 RCT in refractory RA tests whether Phase 2a's 71% ACR50 signal holds in a controlled, larger population with FDA-agreed endpoints
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Other cancers, Neuromuscular diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
5 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.